<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03753919</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE-T1812</org_study_id>
    <secondary_id>2018-001066-42</secondary_id>
    <nct_id>NCT03753919</nct_id>
  </id_info>
  <brief_title>Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial</brief_title>
  <acronym>DUTHY</acronym>
  <official_title>A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MFAR</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre, open label, stratified, exploratory phase II study
      evaluating the efficacy and safety of durvalumab plus tremelimumab in different cohorts of
      patients with thyroid cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort 1: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle. Cell and poorly-differentiated thyroid carcinoma (DTC).
Cohort 2: Advanced medullary thyroid carcinoma (MTC).
Cohort 3: Advanced anaplastic thyroid cancer (ATC).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients without progression of disease at month 6, according RECIST 1.1 criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients alive at month 6 from first dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>42 months</time_frame>
    <description>Response to treatment according to RECIST 1.1 criteria or iRECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 42 months</time_frame>
    <description>Length of time between start of treatment and date of evidenced response and progression of disease according irRECIST or RECIST 1.1 criteria, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>42 months</time_frame>
    <description>Length of time between date of evidenced response and progression of disease according irRECIST or RECIST 1.1 criteria, or death, or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>42 months</time_frame>
    <description>Number and type of adverse events reported throughout the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival</measure>
    <time_frame>42 months</time_frame>
    <description>Length of time between start of treatment and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response status after start of study treatment</measure>
    <time_frame>6 and 12 months after start of the study treatment</time_frame>
    <description>According irRECIST/RECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Metastatic Thyroid Papillary Carcinoma</condition>
  <condition>Metastatic Thyroid Follicular Carcinoma</condition>
  <condition>Metastatic Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalumab + Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks up to 4 cycles followed by durvalumab 1500 mg every 4 weeks until disease progression, unacceptable toxicity or patients' decision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.</description>
    <arm_group_label>Durvalumab + Tremelimumab</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>Subjects will be allocated in each primary tumor cohort to receive durvalumab 1500 mg every 4 weeks (Q4W) plus tremelimumab 75 mg Q4W for up to 4 doses during the first 4 cycles of combined therapy. After the first 4 cycles (or before is tremelimumab is stopped due to toxicity), patients will continue to receive durvalumab 1500 mg Q4W until disease progression or unacceptable toxicity. Cycles are defined by 4 weeks or 28 days.</description>
    <arm_group_label>Durvalumab + Tremelimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained from the subject prior to performing any
             protocol-related procedures, including screening evaluations.

          -  Age ≥ 18 years at time of study entry.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Body weight &gt;30kg.

          -  Confirmed differentiated thyroid cancer (papillary, follicular, poorly differentiated
             and Hürtle cell), medullary thyroid cancer and anaplastic thyroid cancer.

          -  Available tumor and blood samples for translational research

          -  Patients should meet one of the following criteria:

               1. Cohort 1: Patients with locally advanced or metastatic differentiated thyroid
                  cancer (including the subtypes of papillary, follicular, poorly differentiated
                  and Hürthle cell carcinoma) after disease progression on systemic therapy with
                  MKIs. Patients could be recruited in the study after progression on Lenvatinib
                  (regardless prior lines) or progression on at least two prior MKIs which may or
                  not include Lenvatinib. No prior therapy with immune check point inhibitors is
                  allowed. Patients with intolerable toxicity to MKIs that meet the prior inclusion
                  criteria and experience disease progression by RECIST v1.1 after stopping therapy
                  may be included.

               2. Cohort 2: Patients with locally advanced or metastatic medullary thyroid cancer
                  after progression on systemic therapy with MKIs. Patients could be recruited in
                  the study after progression to Vandetanib (regardless prior lines) or progression
                  to at least two prior MKIs that may or not include Vandetanib. No prior therapy
                  with immune check point inhibitors is allowed. Patients with intolerable toxicity
                  to MKIs that meet the prior inclusion criteria and experience disease progression
                  by RECIST v1.1 after stopping therapy may be included.

               3. Cohort 3: Patients with locally advanced or metastatic anaplastic thyroid cancer
                  regardless of prior therapy. No prior therapy with immune check point inhibitors
                  is allowed.

          -  No limitation of number of prior therapies.

          -  Life expectancy &gt;3 months

          -  Adequate normal organ and marrow function as defined below: a) Haemoglobin ≥9.0 g/dL.
             b) Absolute neutrophil count (ANC) &gt; 1500 per mm3. c) Platelet count ≥100,000 per mm3.
             d) Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN). This will not
             apply to patients with confirmed Gilbert's syndrome (persistent or recurrent
             hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
             hepatic pathology), who will be allowed only in consultation with their physician. e)
             AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal. f) Measured
             creatinine clearance (CL) &gt;40 mL/min or Calculated creatinine CL&gt;40mL/min by the
             Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for
             determination of creatinine clearance.

          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for
             female pre- menopausal patients. Women will be considered post-menopausal if they have
             been amenorrheic for 12 months without an alternative medical cause. The following
             age-specific requirements apply: a) Women &lt;50 years of age would be considered
             post-menopausal if they have been amenorrheic for 12 months or more following
             cessation of exogenous hormonal treatments and if they have luteinizing hormone and
             follicle-stimulating hormone levels in the post-menopausal range for the institution
             or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). b) Women
             ≥50 years of age would be considered post-menopausal if they have been amenorrheic for
             12 months or more following cessation of all exogenous hormonal treatments, had
             radiation-induced menopause with last menses &gt;1 year ago, had chemotherapy-induced
             menopause with last menses &gt;1 year ago, or underwent surgical sterilization (bilateral
             oophorectomy, bilateral salpingectomy or hysterectomy).

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up.

        Exclusion Criteria:

          -  Participation in another clinical study with an investigational product during the
             last 21 days.

          -  Concurrent enrolment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study.

          -  Any previous treatment with a PD1, PD-L1 or CTLA-4 inhibitor, including durvalumab and
             tremelimumab.

          -  Any previous treatment with immunotherapy, including combinations of immunotherapy and
             other anticancer or targeted agents.

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Fridericia's Correction.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid. The following are exceptions to this
             criterion: a) Intranasal, inhaled, topical steroids, or local steroid injections
             (e.g., intra articular injection). b) Systemic corticosteroids at physiologic doses
             not to exceed 10 mg/day of prednisone or its equivalent. c) Steroids as premedication
             for hypersensitivity reactions (e.g., CT scan premedication).

          -  Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
             criteria: a) Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case
             basis after consultation with the Study Physician. b) Patients with irreversible
             toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be
             included only after consultation with the Study Physician.

          -  Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.
             Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone
             replacement therapy) is acceptable.

          -  History of allogenic organ transplantation.

          -  Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this
             criterion: a) Patients with vitiligo or alopecia. b) Patients with hypothyroidism
             (e.g., following Hashimoto syndrome) stable on hormone replacement. c) Any chronic
             skin condition that does not require systemic therapy. d) Patients without active
             disease in the last 5 years may be included but only after consultation with the study
             physician. e) Patients with celiac disease controlled by diet alone.

          -  Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring AEs or compromise the ability of the patient to give written
             informed consent.

          -  History of another primary malignancy except for: a) Malignancy treated with curative
             intent and with no known active disease ≥5 years before the first dose of IP and of
             low potential risk for recurrence. b) Adequately treated non-melanoma skin cancer or
             lentigomaligna without evidence of disease. c) Adequately treated carcinoma in situ
             without evidence of disease.

          -  History of active primary immunodeficiency.

          -  Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and TB testing in line with
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients
             with a past or resolved HBV infection (defined as the presence of hepatitis B core
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative
             for HCV RNA.

          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:
             Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to
             30 days after the last dose of IP.

          -  Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ highly effective birth control
             from screening to 90 days after the last dose of durvalumab monotherapy and 180 days
             for combined treatment with durvalumab and tremelimumab.

          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients.

          -  Judgment by the investigator that the patient is unsuitable to participate in the
             study and the patient is unlikely to comply with study procedures, restrictions and
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaume Capdevila, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari Vall d'Hebron, Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Federico Nepote</last_name>
    <phone>+34 93 434 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Verónica Roca</last_name>
    <phone>+34 93 434 44 12</phone>
    <email>investigacion@mfar.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Catalán de Oncología de Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Miren Taberna Sanz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castelló</city>
        <state>Valencia</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>David Lorente Estellés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Antonio Casado Herraez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
    </contact>
    <contact_backup>
      <email>investigacion@mfar.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Lisardo Ugidos de la Varga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico B. Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Francisco Javier Lavernia Giner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Vigo (CHUVI)</name>
      <address>
        <city>Vigo</city>
        <zip>36036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Nepote</last_name>
      <email>investigacion@mfar.net</email>
    </contact>
    <investigator>
      <last_name>Isabel Lorenzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2018</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

